PA-PCI-PHARMA-SERVICES
25.8.2022 16:02:10 CEST | Business Wire | Press release
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, the first facility of its kind to support the growing needs of global developers of biologics in the New England region. The new facility will provide increased flexibility and scalability for secondary packaging, distribution and cold chain storage of innovative therapies in development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005234/en/
“As the northeast biopharma market continues to grow, we are bringing distinctive clinical supply capabilities to the backyard of product development, creating a personalized and responsive approach to evolving client needs,” said Salim Haffar, CEO, PCI Pharma Services. “This newest facility follows our growth in facilities in Berlin, Germany, and Rockford, Illinois, and will create significant local job growth potential.”
To keep pace with the growth in biologics and gene therapies, which require cold chain infrastructure including deep freeze, the new facility has a capacity for a -20° C freezer, 35 ultra-low temperature freezers at -80° C and 12 liquid nitrogen freezers. The Center of Excellence also features a temperature-controlled room containing a 5,000 square foot cooler at 2° to 8° C, each with five levels of warehouse racking. A 1000-square-foot cold secondary packaging room will eventually be converted to primary packaging with the planned construction of an additional secondary packing unit.
“Boston is a booming biotech market with hundreds of local organizations developing new compounds in the biologics space,” said Craig LaMarca, General Manager of Boston Clinical Trial Services, PCI Pharma Services. “The facility features leading technologies and capabilities, making it a crucial component to help our clients deliver life-saving therapies to patients safely and efficiently.”
PCI currently occupies 50,000 square feet of the new 100,000 square foot building, with the remaining space available for lease. The campus was constructed to reflect Environmental Social Governance (ESG) and sustainability efforts. These features include a complex stormwater runoff system with a series of ponds that filter the water before it leaves the site, an underground oil and sedimentation separation tank, electric vehicle chargers and the exclusive use of LED lighting throughout the building.
The opening of the New England Center of Excellence marks the latest in a series of worldwide expansions for PCI including six sites across three continents, including Bedford, New Hampshire; Berlin, Germany; San Diego, California; Rockford, Illinois; and Melbourne, Australia. In February 2022, PCI sites in San Diego and Melbourne added innovative equipment with aseptic fill-finish capabilities to enhance PCI’s global offerings and deliver much-needed capacity to early-phase clinical clients.
For more information on PCI’s aseptic fill-finish and lyophilization capabilities, please click here .
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220825005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PubNub Achieves SOC 3 Compliance, Reinforcing Commitment to Security, Trust, and Transparency5.2.2026 14:00:00 CET | Press release
PubNub, the real-time communications platform that powers low-latency, event-driven logic across modern application architectures, is pleased to announce that it has achieved SOC 3 compliance. This latest attestation highlights PubNub’s continuous dedication to providing a secure and trusted platform for building and scaling interactive online experiences. The SOC 3 report affirms that PubNub’s systems meet the Trust Services Criteria for security, availability, and confidentiality. Unlike SOC 2 reports, which are restricted to existing customers or partners due to the level of operational detail they include, SOC 3 reports are designed for broad, public distribution. This transparency enables anyone to verify that PubNub adheres to the stringent controls required by the SOC 2 framework, providing proof of robust information security and operational integrity. This achievement adds to PubNub’s extensive compliance portfolio, which includes SOC 2 Type 2, ISO/IEC 27001:2022, HIPAA, and G
Visby Medical Collaborates with Watchmaker Genomics to Enhance Respiratory Pathogen Detection in the At-Home Setting5.2.2026 14:00:00 CET | Press release
Visby Medical, a leading innovator in at-home PCR testing of infectious diseases, has announced a strategic collaboration with Watchmaker Genomics, a supplier of innovative products for molecular analysis, to develop next-generation diagnostic tests for respiratory pathogen detection in the at-home setting. This partnership pairs Visby Medical’s instrument-free PCR testing technology – the first and only of its kind – with Watchmaker’s expertise in engineering enzymes to address application-specific performance gaps. Clinical samples collected from patients for at-home testing are typically unprocessed, making them vulnerable to molecular inhibitors that can reduce signal strength and lower assay sensitivity. The need for rapid results in the at-home setting also places unique performance demands on the assays and the enzymes they rely on. “Recent increases in COVID cases involving new strains and the current flu season highlight the need for tests that are reliable and fast,” explaine
Veracode Closes Record Year of Growth and Innovation Amid Surging Demand for Application Risk Management5.2.2026 13:50:00 CET | Press release
Veracode, the global leader in application risk management, today announced a year of significant corporate momentum, product innovation, and customer growth throughout 2025. The company delivered strong performance in the final quarter of 2025, with new Annual Contract Value (ACV) increasing 81 percent year-over-year, underscoring sustained market traction and rising demand for its solutions. Veracode’s strong performance was fueled by growing demand for application risk management as organizations navigated the dual pressures of rapid AI adoption and increasingly complex software supply chains. Security and development teams are now prioritizing comprehensive platforms that deliver visibility, control, and compliance across application ecosystems, helping them meet evolving regulatory requirements and manage modern development risks. “We closed 2025 with an exceptional finish, and this is a direct result of our unwavering commitment to customer success,” said Brian Roche, Chief Execu
Kinaxis Introduces Maestro Agent Studio, Unlocking Next Level Decision Making Through Composable AI Agents5.2.2026 13:01:00 CET | Press release
These composable AI agents reflect how supply chains actually operate Kinaxis® Inc. (TSX: KXS), the leader in supply chain orchestration, today announced Maestro Agent Studio, making the next phase of its AI agent strategy available to customers following the launch of prebuilt Maestro Agents. Maestro Agent Studio gives supply chain teams a no-code way to compose AI agents grounded in their real operating context, using the same data, workflows, and tools planners already rely on, so agents drive real-world outcomes. Built into the Kinaxis Maestro® platform, Maestro Agent Studio enables supply chain teams and leaders to apply their expertise across every day and high-impact supply chain decisions without relying on manual, repetitive tasks or custom code development. Maestro Agent Studio is designed to work with leading large language models, including OpenAI’s GPT and Google Gemini, while keeping agent behavior anchored in Maestro’s trusted data, intelligence, and governance. The real
Introducing RAVE Aerospace: A New Name, Built on a Legacy of In-Flight Innovation5.2.2026 13:00:00 CET | Press release
Kingswood Capital Management completes acquisition of Safran Passenger Innovations and unveils the new RAVE Aerospace name, reflecting the company’s strong heritage of innovation and positioning it for the next phase of growth For nearly two decades, RAVE has been a trusted name in in-flight entertainment and connectivity for customers around the world. Today, that heritage continues under a new company name: RAVE Aerospace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205748681/en/ Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) has completed its acquisition of Safran Passenger Innovations (“SPI”), a leading global provider of in-flight entertainment and connectivity solutions, from Safran, an international aerospace group. As part of the transaction, SPI has been renamed as RAVE Aerospace, which will continue to build on the established RAVE brand that has powered in-flight entertainment a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom